NeuBase Therapeutics, Inc.
NBSE · NASDAQ
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $23 | $53 | $32 | $10 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | -$0 | $0 | $0 | $0 |
| Other Curr. Assets | $1 | $2 | $0 | $0 |
| Total Curr. Assets | $25 | $55 | $33 | $11 |
| Property Plant & Equip (Net) | $8 | $8 | $1 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $1 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $8 | $9 | $2 | $2 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $33 | $64 | $34 | $13 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $2 | $1 |
| Short-Term Debt | $1 | $1 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $1 | $0 |
| Other Curr. Liab. | $2 | $2 | $1 | $0 |
| Total Curr. Liab. | $4 | $4 | $3 | $3 |
| LT Debt | $5 | $6 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | -$0 | $0 | $0 |
| Total NC Liab. | $5 | $6 | $2 | $0 |
| Other Liabilities | $0 | $0 | -$2 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $10 | $10 | $3 | $3 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$103 | -$69 | -$44 | -$27 |
| AOCI | $0 | $0 | -$0 | $0 |
| Other Equity | $126 | $123 | $75 | $37 |
| Total Equity | $23 | $54 | $31 | $10 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $33 | $64 | $34 | $13 |
| Net Debt | -$17 | -$46 | -$32 | -$10 |